Despite this, increasing evidence shows that an inflamed or PD-L1 positive tumor microenvironment is not always sufficient to achieve clinical benefit from immune therapies targeting the PD-L1/PD-1 axis, and combination strategies may be needed to expand the spectrum of patients who respond to them. This evidence concerns the gene CD274 and neoplasm.